Targeting the SREBP-1/Hsa-Mir-497/SCAP/FASN Oncometabolic Axis Inhibits the Cancer Stem-like and Chemoresistant Phenotype of Non-Small Cell Lung Carcinoma Cells.
Tung-Yu TiongPei-Wei WengChun-Hua WangSyahru Agung SetiawanVijesh Kumar YadavNarpati Wesa PikatanIat-Hang FongChi-Tai YehChia-Hung HsuKuang-Tai KuoPublished in: International journal of molecular sciences (2022)
Targeting the SREBP-1/hsa-miR-497 signaling axis is a potentially effective anticancer therapeutic strategy for NSCLC.